Relay Therapeutics has announced a collaboration with Pfizer to conduct a clinical trial for a combination of drugs for treating PI3Kα-mutated, HR+, HER2- metastatic breast cancer.
The trial will assess the combined use of Pfizer's investigative drug atirmociclib with Relay's RLY-2608 and another medication called fulvestrant. This combination of drugs, targeted at specific biomarkers, aims to reduce side effects and increase efficacy. The therapy trial is scheduled to start by the end of 2024.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.